Table 2

Univariate and multivariable analyses of risk factors for H. pylori eradication failure

CharacteristicsNUnivariate analysisMultivariable analysis
OR (95% CI)P valueOR (95% CI)P value
Age
 ≤ 3054001.001.00
 30–4056341.25 (1.12 to 1.41)<0.0011.25 (1.11 to 1.41)<0.001
 40–5037741.43 (1.26 to 1.62)<0.0011.43 (1.26 to 1.62)<0.001
 50–6043101.68 (1.49 to 1.89)<0.0011.70 (1.51 to 1.91)<0.001
 > 6025862.04 (1.79 to 2.32)< 0.0012.01 (1.76 to 2.29)< 0.001
Sex
 Male10 2571.00
 Female11 4470.98 (0.91 to 1.06)0.646
Date of treatment
 201736951.001.00
 201861230.82 (0.73 to 0.91)<0.0010.85 (0.75 to 0.95)0.005
 201967400.86 (0.77 to 0.96)0.0070.90 (0.80 to 1.01)0.071
 202051460.80 (0.71 to 0.90)<0.0010.86 (0.76 to 0.97)0.017
Season
 Spring40081.00
 Summer54890.86 (0.77 to 0.96)0.009
 Autumn58280.88 (0.78 to 0.98)0.021
 Winter63790.88 (0.79 to 0.98)0.024
Antibiotic regimens
 Amoxicillin+furazolidone16 2301.001.00
 Amoxicillin+clarithromycin38851.19 (1.08 to 1.32)0.0011.21 (1.09 to 1.34)<0.001
 Furazolidone+clarithromycin15892.99 (2.66 to 3.36)<0.0012.97 (2.64 to 3.34)<0.001
Duration
 1053481.001.00
 1416 3560.81 (0.75 to 0.89)<0.0010.89 (0.82 to 0.97)0.011
Proton pump inhibitor
 Rabeprazole10mg88261.00
 Rabeprazole20mg211.05 (0.31 to 3.55)0.944
 Pantoprazole54551.11 (1.01 to 1.22)0.029
 Esomeprazole45301.11 (1.00 to 1.23)0.049
 Omeprazole20100.83 (0.72 to 0.96)0.014
 Lansoprazole8621.02 (0.84 to 1.25)0.818